Opinion: Taking the Pulse of Horizon Europe

The plan to revitalize the European innovation landscape is entering a transition.

Written byMarc Baiget Francesch
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ABOVE: © ISTOCK.COM, VJANEZ

With the arrival of 2020, the decade of the 2010s has come to an end, and with it the most ambitious European research and innovation funding program enters its final year. Horizon 2020, the European Union (EU) seven-year plan kickstarted in 2014, is making way for Horizon Europe. This successor program will cover the EU research and innovation strategy between 2021 and 2027, and is poised for transition after a provisional agreement was reached last April between the Council of the EU and the colegislators.

But within this provisional agreement, the final budget—which the European commission proposed to be around €100 billion (more than $111 billion US), a sizeable increase from the €80 billion (more than $89 billion US) that was previously budgeted for Horizon 2020 and about 1.3 percent of the EU total budget—is still not clear. If Horizon Europe’s budget is finalized in this ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies